Eledon Pharmaceuticals to Present Islet Transplant Trial Data at ADA 2026
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Benzinga
Image: Benzinga
Eledon Pharmaceuticals will present updated data from a trial on tegoprubart, an anti-CD40L antibody, at the American Diabetes Association's 86th Scientific Sessions in New Orleans from June 5-9, 2026. The presentation will focus on graft survival and function in islet allotransplantation.
- 01The presentation will be delivered by Dr. Piotr Witkowski, Director of the Pancreas and Islet Transplant Program at UChicago Medicine.
- 02The session is titled 'Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation' and is scheduled for June 7, 2026.
- 03Tegoprubart targets CD40 Ligand, which is crucial for immune cell activation, making it a promising candidate for immunomodulatory therapies.
- 04Eledon Pharmaceuticals specializes in developing therapies for life-threatening conditions, including transplantation and amyotrophic lateral sclerosis (ALS).
- 05The company is based in Irvine, California, and is focused on advancing its investigational products through clinical studies.
Advertisement
In-Article Ad
Eledon Pharmaceuticals, Inc. has announced that updated results from an investigator-initiated trial on tegoprubart will be presented at the American Diabetes Association's 86th Scientific Sessions in New Orleans from June 5-9, 2026. The presentation, titled 'Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation,' will be delivered by Dr. Piotr Witkowski, who leads the Pancreas and Islet Transplant Program at the University of Chicago Medicine. Scheduled for June 7, 2026, from 2:30 p.m. to 3:00 p.m. CT, the session will focus on the role of tegoprubart, an anti-CD40L antibody, in promoting graft survival and function in islet transplantation. Eledon is a clinical-stage biotechnology firm dedicated to developing immune-modulating therapies for severe conditions, with an emphasis on transplantation and ALS. The company is leveraging its expertise in CD40 Ligand biology to explore therapeutic interventions across various transplantation types.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of tegoprubart in islet transplantation?
Connecting to poll...
Read the original article
Visit the source for the complete story.